Wyeth pharmaceuticals and Solvay Pharmaceuticals entered into an agreement to co-develop and co-commercialize four neurological compounds including Solvay’s bifeprunox, which is in phase III clinical trials for treating schizophrenia and other psychotic disorders. Solvay will help to promote Wyeth’s serotonin-noradrenalin reuptake inhibitor, Effexor® XR (venlafazine hydrochloride) in the US.